Business Context and Reporting Period
This Form 8-K Current Report was filed by Seer, Inc. on November 4, 2021, covering events occurring between November 4, 2021, and November 8, 2021. The filing details changes to the Company's Board of Directors, specifically the resignation of one director and the appointment of another.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and director compensation arrangements rather than financial performance.
Material Changes
- Director Resignation: David Singer notified the Board of his intent to resign, effective November 8, 2021. The resignation was not the result of any dispute regarding the Company's operations, policies, or practices.
- Director Appointment: Rachel Haurwitz, Ph.D., was appointed to the Board, effective November 8, 2021, serving as a Class II director with a term expiring at the 2022 annual meeting.
- Committee Assignment: Dipchand (Deep) Nishar was appointed to replace Mr. Singer as a member of the Audit Committee.
Guidance, Outlook, and Compensation Details
The filing outlines the compensatory arrangements for the newly appointed director, Dr. Haurwitz, under the Company's outside director compensation policy:
- Cash Compensation: Annual cash compensation of $40,000 for Board services, plus additional compensation for committee service if applicable.
- Initial Equity Award: An option to purchase 30,000 shares of Class A Common Stock, granted on November 9, 2021. This award vests monthly over 36 months (1/36th per month).
- Future Equity Awards: Eligibility for an annual award of options to purchase 15,000 shares, subject to pro-ration if the director commenced service after the prior annual meeting. These awards vest one year after the grant date or immediately prior to the next annual meeting.
- Change in Control: Equity awards vest in full immediately prior to a change in control, provided the director remains in service through that date.
The filing does not contain management commentary on business outlook, risks, contingencies, or unusual items beyond the standard disclosure of the director changes.
Investor Verification Checklist
- Verify the effective date of the Board composition changes (November 8, 2021).
- Confirm the vesting schedule and terms of the 30,000-share initial option grant to Dr. Haurwitz.
- Review the Company's 2020 Equity Incentive Plan for full terms governing the director awards.
- Check for any subsequent filings regarding the Audit Committee composition following Mr. Singer's departure.